Fierce Health Technology January 13, 2020
Paige Minemyer

CVS Health is taking a multipronged approach to addressing the costs associated with gene therapies.

As more gene therapies are set to come down the pipeline, payers and employers can proactively prepare for those products in several different ways, according to a new white paper from CVS Health.

In the report (PDF), the healthcare giant offers a four-point strategy health plans and plan sponsors can adopt to get out ahead of the costs associated with these treatments, which are set to balloon significantly as they’re applied to more common diseases.

The suggested steps are:

  1. Extend the centers of excellence approach to gene therapy providers.

  1. Continue to evolve the role...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Insurance, Patient / Consumer, Payer, Precision Medicine, Provider, Retail care, Technology
Related Articles:
Halozyme Pulls €2B Acquisition Bid as Evotec Commits to Standalone Strategy
More than half of US adults could benefit from GLP-1 medications, researchers find
RNA editing is the next frontier in gene therapy—here's what you need to know
Rand roadblock: Biotech bill’s uncertain future
How Digital Chemistry Will Improve Cross-Functional Collaboration In The Biopharma Industry

Share This Article